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Objective: The combination of inhaled corticosteroid (ICS) and long-acting β2-agonist is recommended for treatment of patients with per-
sistent asthma inadequately controlled on ICS monotherapy. This study was conducted to evaluate the long-term safety of mometasone
furoate/formoterol (MF/F) administered through metered-dose inhaler (MDI) in patients with persistent asthma previously on medium- to
high-dose ICS. Methods: This was a 52-week, randomized, multicenter, parallel-group, open-label, evaluator-blinded study. At baseline, 404
patients (aged ≥12 years) were stratified according to their previous ICS dose (medium or high), then randomized 2:1 to receive twice-daily
treatment of MF/F (200/10 or 400/10 μg) or fluticasone propionate/salmeterol (FP/S; 250/50 or 500/50 μg). The primary endpoint was the
number and percentage of patients reporting any adverse event (AE). Additional safety evaluations included plasma cortisol 24-hour area under
the curve (AUC0−24 h) and ocular changes. Pulmonary function, asthma symptoms, and use of rescue medication were monitored. Results: The
incidence of ≥1 treatment-emergent AE was similar across treatment groups (MF/F 200/10 μg, 77.3% [n = 109]; FP/S 250/50 μg, 82.4%
[n = 56]; MF/F 400/10 μg, 79.2% [n = 103]; FP/S 500/50 μg, 76.9% [n = 50]). Rates of treatment-related AEs were also similar across
treatment groups (MF/F 200/10 μg, 28.4%; FP/S 250/50 μg, 23.5%; MF/F 400/10 μg, 23.1%; FP/S 500/50 μg, 20.0%). Headache (3.7%)
and dysphonia (2.7%) were the most common treatment-related AEs overall. The nature and frequency of AEs and the decreases in plasma
cortisol AUC0−24 h observed with MF/F treatment were similar to those observed with FP/S treatment. Ocular events were rare (2–6% overall
incidence among treatment groups); in particular, no posterior subcapsular cataracts were reported. Only three patients discontinued the study
because of treatment-related ocular AEs (two for lens disorders in the MF/F 400/10 μg group; one for reduced visual acuity in the FP/S
250/50 μg group) and no asthma-related deaths occurred. Furthermore, MF/F showed numerical improvement in lung function and clinical
benefits by reducing asthma symptoms and rescue medication use. Conclusions: One-year treatment with the new combination therapies –
twice-daily MF/F-MDI 200/10 and 400/10 μg – is safe and well tolerated in patients with persistent asthma.
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INTRODUCTION
Asthma is a chronic respiratory disease characterized
by reversible bronchoconstriction, bronchial hyperrespon-
siveness, and inflammation, with episodes of asthma
worsening occurring in response to various stimuli (1–4).
With their anti-inflammatory properties, inhaled cortico-
steroids (ICSs) are the first-line therapy to relieve persis-
tent asthma symptoms of all severities (1–4). For treat-
ment of patients with moderate to severe asthma who
are not adequately controlled on ICS monotherapy or
whose disease severity warrants treatment with an addi-
tional controller medication, combination therapy with
an ICS and a bronchodilator (e.g., long-acting β2-agonist
[LABA]) is recommended by asthma guidelines (5, 6).
Mometasone furoate (MF), a potent and safe ICS with
high affinity for glucocorticoid receptors, is approved
in the United States for treatment of asthma in adult
and pediatric patients (7). Numerous clinical trials have
demonstrated the efficacy of MF with regard to lung
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function, asthma symptoms, and quality of life as
well as its safety and tolerability at multiple strengths
(100–800 μg) and dosing regimens (8–15). Formoterol
(F), a LABA, when administered as monotherapy, rapidly
dilates airway smooth muscle and maintains control over
24 hours, thereby improving lung function and reducing
asthma symptoms (16–19).
Because individual components of MF/F possess well-
defined efficacy as well as pharmacologic and safety
profiles when administered separately at recommended
doses, the new MF/F combination administered through
a single metered-dose inhaler (MDI) is expected to
exhibit the same characteristics. A 52-week study was
undertaken to determine the long-term safety, includ-
ing cortisol suppression and ocular changes, of MF/F
in patients with persistent asthma previously on mainte-
nance therapy of medium- to high-dose ICS alone or in
combination with a LABA. In addition, the study mon-
itored pulmonary function, asthma symptom scores, res-
cue medication use, and asthma exacerbations to ensure
appropriate disease management. Fluticasone propionate
plus salmeterol (FP/S) MDI, a frequently prescribed
ICS/LABA combination, was selected as the active com-
parator (20, 21).
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METHODS
Study Design
This was a 52-week, randomized, parallel-group, mul-
ticenter, open-label, and evaluator-blinded (third-party
study medication dispenser) study conducted at 27 clin-
ical sites in South America (Argentina, Peru, Ecuador,
Guatemala, Chile, and Mexico) in compliance with Good
Clinical Practice guidelines. The study protocol was
reviewed and approved by institutional review boards.
Written informed consent was obtained from all patients
before study entry.
At screening, eligible patients were instructed to
remain on their medication(s) until 24 hours before base-
line visit and given salbutamol, a short-acting β2-agonist
(SABA) as rescue medication. At baseline, patients were
stratified (Figure 1) according to their previous ICS dose
(medium or high) and randomized 2:1 to receive twice-
daily (BID) treatment of two inhalations per dose of
either MF/F (100/5 or 200/5 μg per inhalation) or FP/S
(125/25 or 250/25 μg per inhalation). All study treat-
ments were administered through MDIs. At the baseline
visit, patients received instructions and training on the
proper use of an MDI using a placebo training inhaler.
Patients were not permitted to use spacer or holding
chamber devices when administering study medication.
Study drug compliance was assessed by monitoring pul-
monary function, symptom score, SABA use, nocturnal
awakenings, and clinical deterioration of asthma; patients
considered nonadherent received instruction on necessary
corrective measures.
Study Population
Patients included in the study were 12 years or older,
diagnosed with persistent asthma of ≥12 months, had
a forced expiratory volume in 1 second (FEV1) ≥50%
predicted values, received medium- or high-dose ICS
with or without LABA for ≥12 weeks before screening,
and were on a stable regimen for >= 2 weeks before
screening. Additional inclusion criteria were evidence of
β2-reversibility (increase in FEV1 of ≥12% and ≥200 mL
within 10–15 minutes of SABA use); normal electro-
cardiogram (ECG), clinical laboratory tests, and chest
radiograph; and adequate contraceptive precautions for
women of childbearing age.
Patients were excluded if they demonstrated a change
>20% in FEV1; required use of >12 inhalations of
SABA or two nebulized treatments with 2.5 mg salbu-
tamol on 2 consecutive days at any time between the
screening and baseline visits; experienced a clinically
judged deterioration (deterioration resulting in emergency
treatment, hospitalization, or treatment with additional
FIGURE 1.—Patient disposition. ICS, inhaled corticosteroid; FP/S, fluticasone propionate/salmeterol combination; MF/F, mometasone furoate/formoterol.
∗Patient population used for safety analyses. †Patient population used for efficacy analyses, identified before database lock.1108 J. F. MASPERO ET AL.
asthma medication other than SABA); had intraocular
pressure ≥22 mmHg in either eye, glaucoma, or evi-
dence of cataract(s) at screening; was a current smoker
(had smoked within the previous year) or ex-smoker (>10
pack-years); received emergency treatment for airway
obstruction in the past 3 months; or suffered a respiratory
infection within 2 weeks before screening.
A full medical history, including asthma, seasonal
allergic rhinitis, and perennial allergic rhinitis, was
obtained at baseline. Patients with a history of clinically
significant medical illness or a disorder, that, in the judg-
ment of the investigator, could interfere with the study
or require treatment that might interfere with the study
were not enrolled. Patients with conditions that were
well controlled and stable (e.g., hypertension not requir-
ing β-blockers) were allowed to participate if deemed
appropriate per the investigator’s judgment.
Assessments of Safety and Efficacy
The primary objectives for the study were the num-
ber and percentage of all randomized patients who
reported adverse events (AEs). A severe AE was any
AE that caused inability to perform usual activities or
significantly affected clinical status and warranted inter-
vention. A serious AE (SAE) was any AE that was
life-threatening or resulted in death, persistent or sig-
nificant disability/incapacity, or required hospitalization.
The secondary objective was an assessment of impact on
hypothalamic–pituitary–adrenal (HPA) axis function as
assayed by plasma cortisol 24-hour area under the curve
(AUC0−24 h) measured at baseline, week 26, and week 52
at selected centers.
Additional safety evaluations were ophthalmologic
tests (applanation tonometry and slit lamp examination
with full dilatation) conducted at screening, week 26, and
week 52 to assess the number and percentage of patients
who had a change of at least 1 unit in lens opacities clas-
sification system (LOCS III) grade (22) or intraocular
pressure ≥22 mmHg; physical examinations; clinical lab-
oratory tests; and measurements of vital signs and ECG.
Per protocol, a change of ≥1 unit in LOCS III grade or
intraocular pressure ≥22 mmHg was considered an SAE,
and patients were to be discontinued from the study.
Clinical evaluations included pulmonary function tests
by spirometry (FEV1, forced expiratory flow [FEF],
forced vital capacity [FVC], percentage predicted FEV1)
and peak flow meter measurements (morning and evening
peak expiratory flow [PEF]); asthma symptom score,
based on daily patient assessment of three asthma symp-
toms (wheezing, difficulty breathing, and cough) each
scored on a scale of 0 (none) to 3 (very uncomfort-
able and interfered with most or all of normal daily
activities/sleep); proportion of asthma-free days and
nights (i.e., no SABA use, no asthma symptoms, 24-hour
PEF variability less than 20% of baseline, no unscheduled
visits to a medical facility, and no nocturnal awaken-
ing); proportion of days and nights without any SABA
use; and clinically judged deterioration (asthma deterio-
ration resulting in emergency treatment, hospitalization,
or treatment with additional asthma medication other
than SABA). FEV1, FVC, and FEF from 25% to 75%
(FEF25–75%) were evaluated at baseline, each study visit,
and endpoint; morning and evening PEF and asthma
symptom scores were evaluated at baseline, each study
month, and endpoint; proportions of days and nights that
were asthma-free or SABA-free were evaluated at base-
line and across the entire treatment period; incidences
of asthma deterioration were recorded across the entire
treatment period.
Statistical Analyses
The sample size necessary to detect an event with a 2%
incidence rate in at least 1 out of 100 patients with a 20%
dropout rate was calculated to be 125. Results of AEs are
tabulated by system organ class as defined by the Medical
Dictionary for Regulatory Activities. Results of plasma
cortisol AUC0−24 h and ophthalmologic examinations are
presented using descriptive statistics for each treatment
group.
Analyses of lung function tests, asthma symptom
scores, proportions of asthma-free days and nights, and
days and nights without SABA use were based on
randomized patients who met eligibility criteria (effi-
cacy evaluable patients). Reasons for excluding patients
from efficacy analyses were (1) failure to meet entrance
criteria, (2) unacceptable baseline FEV1, (3) unaccept-
able concomitant medications, (4) insufficient medication
washout, and (5) noncompliance with study treatment.
These patients were identified after the completion of the
study and before database lock. Because this study was
not powered to determine differences in the outcome of
these parameters between treatment groups, descriptive
statistics are presented.
RESULTS
Study Population
A total of 404 patients with persistent asthma were
enrolled and randomized to receive MF/F 200/10 μg
(n = 141) or FP/S 250/50 μg( n = 68) in the medium-
dose stratum and MF/F 400/10 μg( n = 130) or FP/S
500/50 μg( n = 65) in the high-dose stratum, all admin-
istered BID through MDI. Overall, 345 patients (85%)
completed the study and 59 patients (15%) discontinued
treatment (Figure 1). Two common reasons for discontin-
uation were study noncompliance (n = 17, 4.2%) and
AEs (n = 13, 3.2%), three of which were treatment-
related. All randomized patients (n = 404) were included
in the safety analyses, and all efficacy evaluable patients
(n = 308) were included in the efficacy analyses.
Baseline demographics and disease characteristics
were well matched between treatment groups within
each stratum (Table 1). The majority of patients were
between 18 and 65 years of age (82%), female
(63%), and multiracial nonwhite (53%) with very few
blacks or Asians. At entry, more patients had a body
mass index of ≥25 kg/m2 in the high-dose stratumMOMETASONE FUROATE/FORMOTEROL LONG-TERM SAFETY 1109
TABLE 1.—Patient demographics and baseline characteristics.
Treatment group (MDI-administered; BID)
MF/FF P /SM F /FF P /S
200/10 μg 250/50 μg 400/10 μg 500/50 μg Total
Characteristics (n = 141) (n = 68) (n = 130) (n = 65) (n = 404)
Age, mean (SD), years 32.7(15.2) 32.4(14.9) 39.3(14.5) 37.1(15.0) 35.5(15.2)
Sex, n (%)
Women 92(65) 38(56) 86(66) 40(62) 256 (63)
Men 49(35) 30(44) 44(34) 25(38) 148(37)
Race, n (%)
White 68(48) 30 (44) 60(46) 32(49) 190(47)
Nonwhite (multiracial) 73(52) 38 (56) 70 (54) 33 (51) 214 (53)
Body mass index, mean (SD) (kg/m2) 24.9(4.89) 25.56(5.51) 26.47(4.27) 26.59(5.54) 25.78(4.96)
Asthma duration, mean (SD) (years) 15.32 (11.92) 16.53(12.07) 19.38(13.17) 18.10(12.30) 17.28(12.5)
Baseline FEV1, mean (SD) (L) 2.56(0.76) 2.53(0.8) 2.31(0.72) 2.26 (0.71) 2.42(0.76)
Baseline FEV1, mean (SD) (% predicted) 80.45(15.94) 78.14(16.26) 74.47(15.80) 72.15(17.66) 76.78(16.49)
FEV1, mean (SD) (% reversibility) 21.28(9.54) 23.70(11.74) 24.05(11.68) 24.77(13.86) 23.06(11.27)
Prior ICS use, n (%)∗
Beclomethasone 40(28) 14 (21) 28(22) 15(23) 97(24)
Budesonide 44(31) 24(35) 25(19) 13(20) 106(26)
Ciclesonide 1 (1) 1 (1) 3 (2) 0 5 (1)
Fluticasone 38(27) 21 (31) 46(35) 24 (37) 129(32)
Mometasone 1(1) 0 5(4) 1 (2) 7 (2)
ICS + LABA, n (%)∗
Budesonide/formoterol 3(2) 1(1) 1(1) 0 5(1)
Fluticasone/salmeterol 21 (15) 11 (16) 31 (24) 16 (25) 79 (20)
Prior tobacco use, n (%) 17(12) 4 (6) 15(12) 9 (14) 45 (11)
∗Patients could have used ≥1 ICS and/or ICS + LABA during the 3 months before randomization. BID, twice daily; FEV1, forced expiratory volume in 1 second; FP/S,
fluticasone propionate/salmeterol; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; MDI, metered-dose inhaler; MF/F, mometasone furoate/formoterol.
than the medium-dose stratum (63% vs. 44%, respec-
tively). Mean ICS dose used before randomization was
similar between MF/F and FP/S treatments within
each stratum (861 vs. 905 μg/d in the medium-
dose stratum, and 1431 vs. 1551 μg/d in the high-
dose stratum; all beclomethasone equivalents); overall,
79% of patients did not use a concomitant LABA.
Safety
The majority of patients (83–88%) in each group com-
pleted the 52-week treatment period, thereby having
sufficient exposure to the MF/Fo rF P /S dose to charac-
terize their safety profiles. The number and percentage of
patients reporting any AE in each group were as follows:
MF/F 200/10 μg, n = 109 (77.3%); FP/S 250/50 μg,
n = 56 (82.4%); MF/F 400/10 μg, n = 103 (79.2%);
and FP/S 500/50 μg, n = 50 (76.9%). No noticeable dif-
ferences in the nature or frequency of AEs were observed
between groups (Table 2). The most common AE cate-
gories were infections and infestations; nervous system
disorders; gastrointestinal disorders; and respiratory, tho-
racic, and mediastinal disorders. The majority of AEs
were of mild to moderate severity. About one-third of
AEs in each group were judged by investigators as likely
related to treatment (MF/F 200/10 μg, 36.7%; FP/S
250/50 μg, 28.6%; MF/F 400/10 μg, 29.1%; and FP/S
500/50 μg, 26.0%). The percentage of patients reporting
any treatment-related AEs was similar regardless of dose
or study treatment: MF/F 200/10 μg, 28.4%; FP/S
250/50 μg, 23.5%; MF/F 400/10 μg, 23.1%; and FP/S
500/50 μg, 20.0%. Frequently reported treatment-related
AEs (Table 3) in the two MF/F treatment groups were
dysphonia (4.1%), headache (3.7%), tremor (2.2%), and
aphthous stomatitis (1.5%). Oral candidiasis (1.1%) and
pharyngitis (0.74%) were rare among all patients receiv-
ing MF/F. These results were similar to those observed in
the two FP/S treatment groups; however, zero incidences
of dysphonia or aphthous stomatitis were reported among
patients receiving FP/S.
A total of 21 patients (5.2%) reported severe or life-
threatening AEs: MF/F 200/10 μg, n = 8 (5.7%); FP/S
250/50 μg, n = 4 (5.9%); MF/F 400/10 μg, n = 5
(3.8%); and FP/S 500/50 μg, n = 4 (6.2%). Only 2 of
these 21 patients had severe or life-threatening AEs that
were judged to be treatment related (1 patient with severe
pneumonia and depressed level of consciousness in the
MF/F 200/10 μg group and 1 patient with severe anxiety
in the FP/S 500/10 μg group).
There were 21 patients who reported SAEs: MF/F
200/10 μg, n = 7 (4.9%); FP/S 250/50 μg, n = 4 (5.8%);
MF/F 400/10 μg, n = 8 (6.1%); and FP/S 500/50 μg,
n = 2 (3.1%). Most SAEs were unrelated to treatment,
including two deaths (electrocution and gastric cancer).
No asthma-related deaths or intubations occurred. Only 6
of these 21 patients had SAEs that were judged to be treat-
ment related, including the patient with pneumonia and
depressed level of consciousness mentioned previously.1110 J. F. MASPERO ET AL.
TABLE 2.—Most common treatment-emergent adverse events reported by ≥5.0% of patients in any treatment group.
Treatment group (MDI-administered; BID)
MF/FF P /SM F /FF P /S
200/10 μg 250/50 μg 400/10 μg 500/50 μg Total
MedDRA Classification, n (%) (n = 141) (n = 68) (n = 130) (n = 65) (n = 404)
Infections/ infestations 86(61.0) 46(67.6) 76(58.5) 34(52.3) 242(59.9)
Nasopharyngitis 29(20.6) 13(19.1) 21(16.2) 8(12.3) 71(17.6)
Bronchitis 17(12.1) 14(20.6) 20(15.4) 7(10.8) 58(14.4)
Influenza 14(9.9) 9(13.2) 13(10.0) 11(16.9) 47(11.6)
Pharyngitis 15(10.6) 9(13.2) 11(8.5) 9(13.8) 44(10.9)
Rhinitis 7(5.0) 8(11.8) 7(5.4) 1(1.5) 23(5.7)
URTI 5(3.5) 5(7.4) 5(3.8) 1(1.5) 16(4.0)
Sinusitis 7(5.0) 2(2.9) 4(3.1) 1(1.5) 14(3.5)
Nervous system disorders 47(33.3) 20(29.4) 36(27.7) 13(20.0) 116(28.7)
Headache 33(23.4) 17(25.0) 31(23.8) 13(20.0) 94(23.3)
Gastrointestinal disorders 35(24.8) 22(32.4) 30(23.1) 18(27.7) 105(26.0)
Abdominal pain 4(2.8) 3(4.4) 6(4.6) 5(7.7) 18(4.5)
Abdominal pain upper 3(2.1) 3(4.4) 7(5.4) 3(4.6) 16(4.0)
Aphthous stomatitis 3(2.1) 4(5.9) 3(2.3) 0 10(2.5)
Respiratory, thoracic, mediastinal disorders 42(29.8) 19(27.9) 28(21.5) 11(16.9) 100(24.8)
Rhinitis allergic 11(7.8) 6(8.8) 9(6.9) 5(7.7) 31(7.7)
Pharyngolaryngeal pain 11(7.8) 2(2.9) 7(5.4) 1(1.5) 21(5.2)
Dysphonia 7(5.0) 5(7.4) 5(3.8) 2(3.1) 19(4.7)
Cough 8(5.7) 4(5.9) 2(1.5) 2(3.1) 16(4.0)
Musculoskeletal and connective tissue disorders 21(14.9) 13(19.1) 20(15.4) 11(16.9) 65(16.1)
Back pain 10(7.1) 7(10.3) 6(4.6) 3(4.6) 26(6.4)
Arthralgia 7(5.0) 3(4.4) 4(3.1) 3(4.6) 17(4.2)
Muscle spasms 2(1.4) 2(2.9) 3(2.3) 4(6.2) 11(2.7)
General disorders and administrative site conditions 19(13.5) 9(13.2) 13(10.0) 5(7.7) 46(11.4)
Pyrexia 8(5.7) 4(5.9) 6(4.6) 1(1.5) 19(4.7)
BID, twice daily; FP/S, fluticasone propionate/salmeterol; MDI, metered-dose inhaler; MedDRA, Medical Dictionary for Regulatory Activities; MF/F, mometasone
furoate/formoterol; URTI, upper respiratory tract infection.
TABLE 3.—Most common treatment-related adverse events reported by ≥2.0% of patients in any treatment group.
Treatment group (MDI-administered; BID)
MF/FF P /SM F /FF P /S
200/10 μg 250/50 μg 400/10 μg 500/50 μg Total
MedDRA Classification, n (%) (n = 141) (n = 68) (n = 130) (n = 65) (n = 404)
Nervous system disorders 16 (11.3) 4 (5.9) 6 (4.6) 2 (3.1) 28 (6.9)
Headache 6 (4.3) 4 (5.9) 4 (3.1) 1 (1.5) 15 (3.7)
Tremor 4 (2.8) 0 2 (1.5) 2 (3.1) 8 (2.0)
Infections/Infestations 7 (5.0) 5 (7.4) 8 (6.2) 5 (7.7) 25 (6.2)
Bronchitis 2 (1.4) 2 (2.9) 3 (2.3) 1 (1.5) 8 (2.0)
Oral candidiasis 2 (1.4) 1 (1.5) 1 (0.8) 2 (3.1) 6 (1.5)
Pharyngitis 2 (1.4) 2 (2.9) 0 1 (1.5) 5 (1.2)
Respiratory, thoracic, mediastinal disorders 11 (7.8) 3 (4.4) 6 (4.6) 0 20 (5.0)
Dysphonia 7 (5.0) 0 4 (3.1) 0 11 (2.7)
Gastrointestinal disorders 7 (5.0) 5 (7.4) 4 (3.1) 2 (3.1) 18 (4.5)
Aphthous stomatitis 3 (2.1) 0 1 (0.8) 0 4 (1.0)
Dysphagia 0 2 (2.9) 0 0 2 (0.5)
Musculoskeletal and connective tissue disorders 4 (2.8) 3 (4.4) 4 (3.1) 3 (4.6) 14 (3.5)
Arthralgia 2 (1.4) 3 (4.4) 1 (0.8) 1 (1.5) 7 (1.7)
Muscle spasms 1 (0.7) 1 (1.5) 2 (1.5) 2 (3.1) 6 (1.5)
Eye disorders 3 (2.1) 1 (1.5) 5 (3.8) 0 9 (2.2)
Lens disorders 0 1 (1.5) 3 (2.3) 0 4(1.0)
BID, twice daily; FP/S, fluticasone propionate/salmeterol; MDI, metered-dose inhaler; MedDRA, Medical Dictionary for Regulatory Activities; MF/F, mometasone
furoate/formoterol.
The other five patients reported SAEs of mild to moder-
ate eye disorders: 4 (3.1%) in the MF/F 400/10 μg group
and 1 (1.5%) in the FP/S 250/50 μg group.
Plasma Cortisol AUC0−24 h
The safety of long-term use of MF/F was further evalu-
ated by measuring changes in plasma cortisol AUC0−24 hMOMETASONE FUROATE/FORMOTEROL LONG-TERM SAFETY 1111
FIGURE 2.—Mean plasma cortisol 24-hour AUC at baseline, week 26, and week 52. Patients who had both 0- and 24-hour measurements were included in the
analysis. AUC, area under the curve; FP/S, fluticasone propionate/salmeterol; MF/F, mometasone furoate/formoterol.
∗p ≤ .043 versus baseline within treatment groups.
in 57 patients (Figure 2). Mean baseline plasma cortisol
AUC0−24 h levels were higher in the MF/F 200/10 μg
and FP/S 500/50 μg groups (210.5 and 238.3 μg • h/dL,
respectively) than in the MF/F 400/10 μg and FP/S
250/50 μg groups (188.8 and 189.2 μg • h/dL), which
was likely because of high values found in three indi-
viduals (two in the MF/F and one in the FP/S groups).
Compared with the baseline values, there were sus-
tained statistically significant reductions in plasma cor-
tisol AUC0−24 h in all treatment groups (p ≤ .043) at
weeks 26 and 52, with the exception of a nonsignificant
reduction for FP/S 250/50 μg at week 52 (p = .076). At
week 26, the extents of decreases were 37.5% for MF/F
200/10 μg, 28.8% for FP/S 250/50 μg, 33.3% for MF/F
400/10 μg, and 22.3% for FP/S 500/50 μg. At week 52,
the corresponding decreases were 2.2%, 16.7%, 29.6%,
and 32.2%.
Ocular Changes
For all treatments, ophthalmologic examinations revealed
a low incidence of ocular events as defined by the percent-
age of patients with a LOCS III grade change of at least
1 unit during the study: MF/F 200/10 μg, 3.5% (n = 5);
FP/S 250/50 μg, 5.9% (n = 4); MF/F 400/10 μg,
3.8% (n = 5); and FP/S 500/50 μg, 1.5% (n = 1).
Furthermore, there was no report of posterior subcapsu-
lar cataracts in any treatment group. Of the 15 patients
reportingocularchanges, 5experiencedchangesthatwere
considered by the investigator as being possibly related to
study treatment (all considered SAEs): 3 with a lens dis-
order, 1 with ocular hypertension (all MF/F 400/10 μg),
and 1 with reduced visual acuity (FP/S 250/50 μg).
Treatment was discontinued for two of the patients with
lens disorder and the patient with reduced visual acuity.
Assessments of Lung Function, Asthma Symptoms, and
Other Asthma-Related Parameters
At baseline, patients in the medium-dose stratum had
higher FEV1 values (MF/F 200/10 μg, 2.65 L and FP/S
250/50 μg, 2.62 L) than those in the high-dose stra-
tum (MF/F 400/10 μg, 2.31 L and FP/S 500/50 μg,
2.41 L), indicating less impairment in lung function in the
medium-dose stratum. Analyses of pulmonary function
tests revealed that patients showed improvements in lung
function across all treatment groups as early as week 1.
At week 52, FEV1 values increased on average by 10.7%,
15.0%, 11.7%, and 14.8% for MF/F 200/10 μg, FP/S
250/50 μg, MF/F 400/10 μg, and FP/S 500/50 μg,
respectively. Similarly, other spirometry measures (per-
centage predicted FEV1, FVC, and FEF25–75%) demon-
strated increases from baseline in all treatment groups
(data not shown), providing further evidence for improved
lung function. Measurements of PEF, which were taken
twice daily by patients before study medications, showed
mean percentage increases from baseline to month 12
in both morning PEF (MF/F 200/10 μg, 21.0%; FP/S
250/50 μg, 18.6%; MF/F 400/10 μg, 14.5%; FP/S
500/50 μg, 9.6%) and evening PEF (21.5%, 18.8%,
13.6%, 8.9%, respectively). Percentage increases from
baseline were observed at every time point measured
throughout the study, beginning with month 1.
Patient-assessed mean 24-hour total asthma symptom
scores were lower (i.e., improved) in the medium-dose
stratum (MF/F 200/10 μg, 1.29; FP/S 250/50 μg, 1.18)
than in the high-dose stratum (MF/F 400/10 μg, 1.60;1112 J. F. MASPERO ET AL.
FIGURE 3.—Improvement in mean 24-hour total asthma symptom scores. Total asthma symptom scores are the sum of wheezing, coughing, and difficulty
breathing scores, based on a scale of 0 (none) to 3 (severe). FP/S, fluticasone propionate/salmeterol; MF/F, mometasone furoate/formoterol.
FP/S 500/50 μg, 1.82) at baseline. All scores in all
treatment groups were lower at each monthly visit dur-
ing the study and at study endpoint compared with
baseline (Figure 3). Absolute changes from baseline in
mean 24-hour total asthma symptom scores at study end-
point represented improvement of 63.9% with MF/F
200/10 μg, 45.0% with FP/S 250/50 μg, 34.5% with
MF/F 400/10 μg, and 48.2% with FP/S 500/50 μg.
Furthermore, proportion of asthma-free days and nights
(i.e., no SABA use, no asthma symptoms, 24-hour PEF
variability less than 20% of baseline, no unscheduled vis-
its to a medical facility, and no nocturnal awakening)
increased by 3.6-fold with MF/F 200/10 μg, 4.3-fold
with FP/S 250/50 μg, 9.3-fold with MF/F 400/10 μg,
and 3.4-fold with FP/S 500/50 μg. The proportions of
days and nights free of SABA use increased by 47%,
65%, 78%, and 100% in the MF/F 200/10 μg, FP/S
250/50 μg, MF/F 400/10 μg, and FP/S 500/50 μg
treatment groups, respectively.
During the study period, 56 randomized patients
(13.9%) experienced a clinically judged deterioration
resulting in emergency treatment, hospitalization, or treat-
ment with additional asthma medications, but none of
them were life-threatening. The percentage of patients
with a clinically judged deterioration was similar between
treatment groups within each stratum: 9.9% (MF/F
200/10 μg) versus 8.8% (FP/S 250/50 μg) in the
medium-dose stratum and 17.7% (MF/F 400/10 μg)
versus 20.0% (FP/S 500/50 μg) in the high-dose stratum.
DISCUSSION
This was the first study to assess the long-term
safety of novel MF/F combination therapy in patients
with persistent asthma. The study demonstrated that
MDI-administered MF/F 200/10 and 400/10 μgB I D
were well tolerated and exhibited safety profiles simi-
lar to those of the individual components (12, 13, 18,
23) as well as of FP/S at equivalent doses (20, 21).
There were no asthma-related deaths or intubations, and
only two patients on MF/F discontinued the study owing
to treatment-related AEs. The percentages of patients
reporting at least 1 AE while receiving either MF/F
treatment was comparable to those observed in two
recent 52-week studies of budesonide/formoterol MDI
320/9 μg BID combination therapy in patients with
asthma(24, 25).Becausemonocomponenttreatmentarms
were not included in this study, direct comparisons of
safety data between MF/F, MF, and F are not possible.
However, data from two shorter studies, including a 26-
week study (MF/F 200/10 μg, MF 200 μg, F 10 μg,
and placebo treatment groups) (26) and a 12-week study
(MF/F 200/10 μg, MF/F 400/10 μg, and MF 400 μg
treatment groups) (27) indicated that no new signals were
observed for MF/F compared with its monocomponents.
Although dysphonia is a common AE associated with
ICS monotherapy (28, 29), the incidence of dysphonia
was low in this study. Similarly, the incidence of oral
candidiasis was low. In addition, reports of tremor and
muscle spasms, AEs commonly associated with LABA
use(30, 31), werevery lowamong all patients treated with
MF/F. No clinically abnormal changes in ECG measure-
ments, vital signs, or plasma potassium levels were seen
with MF/F treatment. Taken together, these data demon-
strate that long-term use of MF/F at either dose raised no
specific safety issues.
Because high doses of exogenous glucocorticoids can
potentially suppress the production of endogenous corti-
sol, HPA-axis suppression is often used to measure a sys-
temic activity of corticosteroids (23, 28, 32, 33). PreviousMOMETASONE FUROATE/FORMOTEROL LONG-TERM SAFETY 1113
studies indicated minimal effects of MF on plasma and
urinary cortisol levels at recommended doses; however,
at higher doses a significant HPA-axis suppression was
observed that was similar to the effects seen with high
doses of FP (7, 29, 34, 35). In this study, there were sta-
tistically significant decreases from baseline in plasma
cortisol AUC0−24 h for all treatment groups at week 26
and for three of the four treatment groups at week 52.
There is no clear explanation for these decreases because
theequivalentICSdosesofbothstudytreatmentswerenot
higher than the patients’ previous ICS doses. One possible
explanation for this is that patients’ compliance with med-
ication improved once they were on study drug; however,
data are not available to confirm this hypothesis. Although
clinical relevance of these decreases could not be ascer-
tained owing to lack of placebo group, the finding that
the extent of decreases in plasma cortisol AUC0−24 h in
the MF/F treatment groups was similar to those seen in
the FP/S groups suggests an acceptable safety profile of
MF/F with regard to this systemic side effect at the doses
tested.
This was the first study to measure effects of MF/Fo n
potential ocular changes using LOCS III system. Overall,
there were only five treatment-related ocular changes
of mild to moderate intensity. More importantly, ocular
changes associated with steroid treatment such as poste-
rior subcapsular cataract and glaucoma were absent. This
outcome is similar to the results reported in other 52-
week studies in which only minor effects were seen in
mean changes in LOCS III scores or intraocular pres-
sureusingotherICStreatmentforasthma:ciclesonideand
beclomethasone dipropionate in adult patients (36) and FP
in pediatric patients (37).
Although this study was not designed to evaluate clin-
ical benefits of MF/F, lung function tests and other
asthma-relatedclinicaloutcomesweremeasuredtoensure
that MF/F treatment had no adverse impact on patients’
health. Study results showed that following the switch
from prestudy treatment (medium- or high-dose ICS
administered with or without LABA) to MF/F study
treatment, patients experienced rapid improvements in
respiratory function and asthma symptoms that were sus-
tained throughout the 52-week MF/F treatment period.
Furthermore, clinically judged deteriorations occurred
infrequently in MF/F treatment groups and with simi-
lar frequency as in the comparative FP/S groups (i.e.,
within medium- and high-dose strata). Importantly, no
case of clinically judged deterioration was considered
life-threatening in this study. These clinical outcomes are
consistentwiththepositiveefficacyoutcomesreportedfor
long-term (52 weeks) FP/S and budesonide/formoterol
studies of patients with persistent asthma (38, 39),
although it is important to note that differences between
these studies and our current study (e.g., dry powder
inhalers vs. MDI devices, patient age range, dosing reg-
imen) make it difficult to make direct comparisons.
Collectively, our findings confirm those of previ-
ous long-term ICS/LABA combination studies (38, 39)
in which no new or unexpected safety concerns were
observed compared with the collective safety histories of
the individual monocomponents. However, further inves-
tigations are needed given the current concerns regarding
the use of long-term LABA therapy (40).
The open-label design of this study is a potential
limitation because it may bias the patient or observer.
Furthermore, the clinical relevance of some evaluations in
this study such as plasma cortisol and ocular change are
difficult to ascertain because of the lack of a placebo con-
trol. Although a placebo comparator was not included in
this study, use of the medium- and high-dose FP/S active-
treatment arms did allow for direct comparison of MF/F
and FP/S safety, tolerability, and efficacy outcomes based
on dose stratum.
In conclusion, long-term (52 weeks) MF/F-MDI
200/10 and 400/10 μg BID treatments were well tol-
erated, with safety profiles similar to the known safety
profiles of the individual MF and F components and to
FP/S at equivalent doses. Furthermore, no new safety
findings were detected during either MF/F treatment.
Long-term MF/F treatments were also associated with
rapid improvements in respiratory function and asthma
symptoms, which were sustained over the 52-week treat-
ment period. Taken together, these results suggest that
MF/F 200/10 and 400/10 μg BID combination therapies
delivered through an MDI are safe and well tolerated and
present new and convenient options for the treatment of
persistent asthma in adolescents and adults.
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APPENDIX 1
Investigator List
Argentina: Enrique Casal, Buenos Aires; Hector Defranchi, Buenos Aires;
Carlos G. Di Bartolo, Cuidad Autonoma de Buenos Aires; Alberto L.
Dolmann, Florida; Jose E. Jares, Ramos Mejia; Jorge F. Maspero, Ciudad de
Buenos Aires; Luisa B. Rey, Buenos Aires; Ahahi Yanez, Ciudad de Buenos
Aires. Chile: Carlos Bisbal, Rancagua; Susana Munoz, Talcahuano; Tamara
Soler, Santiago. Ecuador: Eduardo Castro, Quito; Ivan Cherrez, Guayaquil;
Rene Cordova, Cuenca; Efrén Guerrero, Quito. Guatemala: Victor Chur,
Gualtemala; Edgar Contreras, Guatemala; Jeremias Guerra, Guatemala;
Gerardo Martinez, Guatemala. Mexico: Jesus J. Moran-Ochoa, Lomas de
Sotelo, D.F.; Chavira M. Perez, Mexico D.F. Peru: Marco Camere, Lima;
William Chavez, Lima; Octavio Cubas, Lima; Felix Efrain, Lima; Andres
Pineiro, Lima; Danilo Salazar, Lima.